TRAILR4/TNFRSF10D/DcR2 Antibody (104918) [Unconjugated]

In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50 is typically 0.3-1.8 µg/mL.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready, ELISA(Cap)
• Clone: 104918
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TRAILR4/TNFRSF10D/DcR2 Antibody (104918) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D
  Ala56-His211
  Accession # Q9UBN6
• Specificity: Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF‑ alpha, and rhTNF-beta is observed.
• Details of Functionality: ActivityAssaywCitation not found None None None
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF10D
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 2.5 ug/10^6 cells
  • CyTOF-ready
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • Neutralization 0.04-0.2 ug/mL
  • ELISA Standard (Matched Pair)
• Application Notes: ELISA Detection: Human TRAIL R4/TNFRSF10D Biotinylated Antibody (Catalog number BAF633)
  Standard: Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog number 633-TR)
• Control:

  TRAILR4/TNFRSF10D/DcR2 Knockout HeLa Cell Lysate

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR4/TNFRSF10D/DcR2 Antibody (104918) [Unconjugated]

• CD264 antigen
• CD264
• DcR2
• DCR2decoy with truncated death domain
• Decoy receptor 2
• TNF receptor-related receptor for TRAIL
• TNF-related apoptosis-inducing ligand receptor 4
• TNFRSF10D
• TRAIL R4
• TRAILR4
• TRAIL-R4
• TRAILR4TRAIL receptor 4
• TRUNDDTRAIL receptor with a truncated death domain
• tumor necrosis factor receptor superfamily member 10D
• tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain

Background

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
2. Pan, G. et al. (1998) FEBS lett 424:41.
3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR4/TNFRSF10D/DcR2 Antibody (MAB633)(14)

Publications using MAB633

• L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps PLoS ONE, 2018;13(6):e0198203. 2018 [PMID: 29927992] (Flow Cytometry, Human)
• Neumann S, Hasenauer J, Pollak N, Scheurich P Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem, 2014;289(23):16576-87. 2014 [PMID: 24764293]
• Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res, 2014;34(2):729-34. 2014 [PMID: 24511006] (Flow Cytometry, Rat)
• TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther., 2012;19(9):652-8. 2012 [PMID: 22767216] (Flow Cytometry, Human)
• Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J. Cell. Physiol., 2010;222(2):357-64. 2010 [PMID: 19877156] (Flow Cytometry, Human)
• Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood, 2009;114(18):3854-63. 2009 [PMID: 19690337] (Flow Cytometry, Human)
• Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells, 2008;26(11):2955-63. 2008 [PMID: 18772312] (Flow Cytometry, Human)
• Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol. Cancer Ther., 2008;7(8):2328-38. 2008 [PMID: 18723480] (Flow Cytometry, Human)
• Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene, 2008;27(30):4161-71. 2008 [PMID: 18345033] (Flow Cytometry, Human)
• Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ., 2008;15(4):718-729. 2008 [PMID: 18202704] (Flow Cytometry, Human)
• Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J. Cell. Biochem., 2008;104(2):595-605. 2008 [PMID: 18092340] (Flow Cytometry, Human)
• Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol. Cancer Ther., 2007;6(12):3219-28. 2007 [PMID: 18065493] (Flow Cytometry, Human)
• Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J. Invest. Dermatol., 2007;127(10):2425-37. 2007 [PMID: 17495957] (Flow Cytometry, Human)
• Singh TR, Shankar S, Srivastava RK HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene, 2005;24(29):4609-23. 2005 [PMID: 15897906] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: TNFRSF10D
• Uniprot:
  • Q9UBN6()